Logo

CombiMatrix Shares Up 6 Percent on News That EAI Will Deploy Its Flu Array

May 17, 2006

NEW YORK, May 17 (GenomeWeb News) - Shares in CombiMatrix were up 6 percent, or $.13, at $2.29 in mid-afternoon trading after the company said EAI, a subsidiary of Science Applications International Corporation, will deploy its array-based influenza screening technology.

 

As GenomeWeb News reported today, CombiMatrix said the deal "gets our technology into the field and into the hands of people and groups standing watch on US soil," said CMBX's CEO Amit Kumar.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.